

# Robert Jenq

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4997570/robert-jenq-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

104  
papers

10,877  
citations

38  
h-index

104  
g-index

113  
ext. papers

14,391  
ext. citations

13  
avg, IF

5.7  
L-index

#	Paper	IF	Citations
104	Performance determinants of unsupervised clustering methods for microbiome data.. <i>Microbiome</i> , <b>2022</b> , 10, 25	16.6	2
103	Gut Microbiome Alterations Associated with Diabetes in Mexican Americans in South Texas.. <i>MSystems</i> , <b>2022</b> , e0003322	7.6	0
102	Financial incentives to increase stool collection rates for microbiome studies in adult bone marrow transplant patients.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0267974	3.7	
101	Dosing a synbiotic of human milk oligosaccharides and B. <i>Infantis</i> leads to reversible engraftment in healthy adult microbiomes without antibiotics.. <i>Cell Host and Microbe</i> , <b>2022</b> ,	23.4	2
100	Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response.. <i>Science</i> , <b>2021</b> , 374, 1632-1640	33.3	52
99	Alloreactive T cells deficient of the short-chain fatty acid receptor GPR109A induce less graft-versus-host disease. <i>Blood</i> , <b>2021</b> ,	2.2	2
98	Nutrition As a Predictor of Microbiome Injury in Allo-HCT. <i>Blood</i> , <b>2021</b> , 138, 746-746	2.2	
97	Flow Cytometric Analysis of Microbial Diversity in Patients with Aggressive Lymphoma Disease Undergoing Chemoimmunotherapy. <i>Blood</i> , <b>2021</b> , 138, 4005-4005	2.2	
96	Gut Microbiome Features Associated with Liver Fibrosis in Hispanics, a Population at High Risk for Fatty Liver Disease. <i>Hepatology</i> , <b>2021</b> ,	11.2	5
95	Bayesian compositional regression with structured priors for microbiome feature selection. <i>Biometrics</i> , <b>2021</b> , 77, 824-838	1.8	2
94	Associations between the gut microbiome and fatigue in cancer patients. <i>Scientific Reports</i> , <b>2021</b> , 11, 5847	4.9	6
93	Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 3039-3049	12.9	3
92	Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer. <i>Genome Medicine</i> , <b>2021</b> , 13, 107	14.4	15
91	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. <i>Nature Medicine</i> , <b>2021</b> , 27, 1432-1441	50.5	57
90	Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study. <i>Blood</i> , <b>2021</b> , 137, 1527-1537	2.2	12
89	Enteropathogenic <i>Escherichia coli</i> Infection in Cancer and Immunosuppressed Patients. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 72, e620-e629	11.6	3
88	IL-22-dependent dysbiosis and mononuclear phagocyte depletion contribute to steroid-resistant gut graft-versus-host disease in mice. <i>Nature Communications</i> , <b>2021</b> , 12, 805	17.4	9

87	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. <i>Nature Medicine</i> , <b>2021</b> , 27, 504-514	50.5	105
86	ProgPerm: Progressive permutation for a dynamic representation of the robustness of microbiome discoveries. <i>BMC Bioinformatics</i> , <b>2021</b> , 22, 126	3.6	0
85	Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. <i>Nature Communications</i> , <b>2021</b> , 12, 5045	17.4	6
84	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 817-835		5
83	The role of microbiota in allogeneic hematopoietic stem cell transplantation. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 21, 1121-1131	5.4	2
82	Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC). <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 5038-5048	12.9	1
81	Microbiome-intestine cross talk during acute graft-versus-host disease. <i>Blood</i> , <b>2020</b> , 136, 401-409	2.2	16
80	Uncovering the role of the gut microbiota in immune checkpoint blockade therapy: A mini-review. <i>Seminars in Hematology</i> , <b>2020</b> , 57, 13-18	4	6
79	Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 822-834	59.2	204
78	Interleukin-22-mediated host glycosylation prevents <i>Clostridioides difficile</i> infection by modulating the metabolic activity of the gut microbiota. <i>Nature Medicine</i> , <b>2020</b> , 26, 608-617	50.5	58
77	An alpha-defensin gene single nucleotide polymorphism modulates the gut microbiota and may alter the risk of acute graft-versus-host disease. <i>British Journal of Haematology</i> , <b>2020</b> , 189, 926-930	4.5	2
76	Microbiome Anomalies in Allogeneic Hematopoietic Cell Transplantation. <i>Annual Review of Medicine</i> , <b>2020</b> , 71, 137-148	17.4	5
75	aPCoA: covariate adjusted principal coordinates analysis. <i>Bioinformatics</i> , <b>2020</b> , 36, 4099-4101	7.2	3
74	Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma. <i>Blood</i> , <b>2020</b> , 136, 34-35	2.2	
73	TCR Repertoires in Graft-Versus-Host-Disease (GVHD)-Target Tissues Reveals Tissue Specificity of the Alloimmune Response. <i>Blood</i> , <b>2020</b> , 136, 21-23	2.2	
72	Neutropenic Enterocolitis: Clinical Features and Outcomes. <i>Diseases of the Colon and Rectum</i> , <b>2020</b> , 63, 381-388	3.1	5
71	Oral microbiome and onset of oral mucositis in patients with squamous cell carcinoma of the head and neck. <i>Cancer</i> , <b>2020</b> , 126, 5124-5136	6.4	6
70	Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness. <i>Blood</i> , <b>2020</b> , 136, 1903-1906	2.2	11

69	Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis <b>2019</b> , 7, 242		31
68	Microbiome and Allogeneic Hematopoietic Stem Cell Transplantation <b>2019</b> , 141-154		
67	Fecal Microbiome, Metabolites, and Stem Cell Transplant Outcomes: A Single-Center Pilot Study. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, ofz173	1	20
66	Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. <i>Cell</i> , <b>2019</b> , 178, 795-806.e12	56.2	389
65	pldist: ecological dissimilarities for paired and longitudinal microbiome association analysis. <i>Bioinformatics</i> , <b>2019</b> , 35, 3567-3575	7.2	9
64	Lactose drives expansion to promote graft-versus-host disease. <i>Science</i> , <b>2019</b> , 366, 1143-1149	33.3	106
63	Fecal Microbiota Transplantation: Restoring the Injured Microbiome after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, e17-e22	4.7	31
62	The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 1322-1340	4.7	64
61	Production of BMP4 by endothelial cells is crucial for endogenous thymic regeneration. <i>Science Immunology</i> , <b>2018</b> , 3,	28	53
60	Suppression of luteinizing hormone enhances HSC recovery after hematopoietic injury. <i>Nature Medicine</i> , <b>2018</b> , 24, 239-246	50.5	20
59	Nutritional Support from the Intestinal Microbiota Improves Hematopoietic Reconstitution after Bone Marrow Transplantation in Mice. <i>Cell Host and Microbe</i> , <b>2018</b> , 23, 447-457.e4	23.4	53
58	Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. <i>Science</i> , <b>2018</b> , 359, 97-103	33.3	1895
57	Loss of Microbiota Diversity after Autologous Stem Cell Transplant Is Comparable to Injury in Allogeneic Stem Cell Transplant. <i>Blood</i> , <b>2018</b> , 132, 608-608	2.2	3
56	Oral Nutrition Modulates the Intestinal Barrier Following Cytotoxic Therapy Via the Microbiome. <i>Blood</i> , <b>2018</b> , 132, 63-63	2.2	
55	Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. <i>Nature Medicine</i> , <b>2018</b> , 24, 1804-1808	50.5	297
54	Implicating or exonerating the gut microbiome in blood-borne infection. <i>Nature Medicine</i> , <b>2018</b> , 24, 1788-1789	50.5	2
53	Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant. <i>Science Translational Medicine</i> , <b>2018</b> , 10,	17.5	170
52	Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. <i>Nature Medicine</i> , <b>2017</b> , 23, 242-249	50.5	135

51	MiRKAT-S: a community-level test of association between the microbiota and survival times. <i>Microbiome</i> , <b>2017</b> , 5, 17	16.6	27
50	Lactobacillus rhamnosus GG probiotic enteric regimen does not appreciably alter the gut microbiome or provide protection against GVHD after allogeneic hematopoietic stem cell transplantation. <i>Clinical Transplantation</i> , <b>2017</b> , 31, e12947	3.8	32
49	Microbiota Disruption Induced by Early Use of Broad-Spectrum Antibiotics Is an Independent Risk Factor of Outcome after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 845-852	4.7	133
48	RIG-I/MAVS and STING signaling promote gut integrity during irradiation- and immune-mediated tissue injury. <i>Science Translational Medicine</i> , <b>2017</b> , 9,	17.5	72
47	Loss of thymic innate lymphoid cells leads to impaired thymopoiesis in experimental graft-versus-host disease. <i>Blood</i> , <b>2017</b> , 130, 933-942	2.2	39
46	Protective Factors in the Intestinal Microbiome Against Clostridium difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Journal of Infectious Diseases</i> , <b>2017</b> , 215, 1117-1123	17.23	56
45	Can Consideration of the Microbiome Improve Antimicrobial Utilization and Treatment Outcomes in the Oncology Patient?. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 3263-3268	12.9	21
44	Intestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1650-1659	2.2	169
43	Not just leukemia: CMV may protect against lymphoma recurrence after allogeneic transplant. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 759-761	1.9	2
42	Clinical Evidence for the Microbiome in Inflammatory Diseases. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 400	8.4	33
41	Role of the intestinal mucosa in acute gastrointestinal GVHD. <i>Blood</i> , <b>2016</b> , 128, 2395-2402	2.2	26
40	Role of gut flora after bone marrow transplantation. <i>Nature Microbiology</i> , <b>2016</b> , 1, 16036	26.6	28
39	Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 339ra71	17.5	284
38	Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease. <i>Nature Immunology</i> , <b>2016</b> , 17, 505-513	19.1	366
37	Suppression of Luteinizing Hormone Enhances HSC Recovery after Hematopoietic Injuries. <i>Blood</i> , <b>2016</b> , 128, 370-370	2.2	
36	Role of the intestinal mucosa in acute gastrointestinal GVHD. <i>Hematology American Society of Hematology Education Program</i> , <b>2016</b> , 2016, 119-127	3.1	5
35	Antibiotic prophylaxis in allogeneic stem cell transplantation-what is the correct choice?. <i>Bone Marrow Transplantation</i> , <b>2016</b> , 51, 1071-2	4.4	
34	Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 1373-83	4.7	415

33	Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 920-5	4.7	26
32	Emerging Influence of the Intestinal Microbiota during Allogeneic Hematopoietic Cell Transplantation: Control the Gut and the Body Will Follow. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 1360-6	4.7	34
31	Role of intestinal microbiota in transplantation outcomes. <i>Best Practice and Research in Clinical Haematology</i> , <b>2015</b> , 28, 155-61	4.2	38
30	Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. <i>Nature</i> , <b>2015</b> , 517, 205-8	50.4	1064
29	High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation. <i>Blood</i> , <b>2015</b> , 125, 199-205	2.2	91
28	Intestinal microbiota-related effects on graft-versus-host disease. <i>International Journal of Hematology</i> , <b>2015</b> , 101, 428-37	2.3	42
27	Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration. <i>Nature</i> , <b>2015</b> , 528, 560-564	50.4	573
26	Gut microbiota and tacrolimus dosing in kidney transplantation. <i>PLoS ONE</i> , <b>2015</b> , 10, e0122399	3.7	88
25	The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , <b>2014</b> , 124, 1174-82	2.2	531
24	Impact of the Intestinal Microbiota on Infections and Survival Following Hematopoietic Stem Cell Transplantation. <i>Blood</i> , <b>2014</b> , 124, SCI-48-SCI-48	2.2	5
23	Early Clostridium difficile infection during allogeneic hematopoietic stem cell transplantation. <i>PLoS ONE</i> , <b>2014</b> , 9, e90158	3.7	60
22	Enhanced responses to tumor immunization following total body irradiation are time-dependent. <i>PLoS ONE</i> , <b>2013</b> , 8, e82496	3.7	10
21	Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease. <i>Immunity</i> , <b>2012</b> , 37, 339-50	32.3	414
20	Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. <i>Clinical Infectious Diseases</i> , <b>2012</b> , 55, 905-14	11.6	561
19	Repertoire enhancement with adoptively transferred female lymphocytes controls the growth of pre-implanted murine prostate cancer. <i>PLoS ONE</i> , <b>2012</b> , 7, e35222	3.7	4
18	Interleukin-22 drives endogenous thymic regeneration in mice. <i>Science</i> , <b>2012</b> , 336, 91-5	33.3	275
17	Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. <i>Journal of Experimental Medicine</i> , <b>2012</b> , 209, 903-11	16.6	438
16	Age-Related Thymic Involution Triggers Intrinsic Regeneration Pathways but They Remain Ineffective for Its Renewal. <i>Blood</i> , <b>2012</b> , 120, 1043-1043	2.2	

15	Over-Expression of TRAIL on Donor T Cells Enhances GVT and Suppresses Gvhd Via Elimination of Alloreactive T Cells and Host APC. <i>Blood</i> , <b>2011</b> , 118, 817-817	2.2	0
14	Innate Lymphoid Cell-Derived IL-22 Mediates Endogenous Thymic Repair Under the Control of IL-23. <i>Blood</i> , <b>2011</b> , 118, 143-143	2.2	
13	Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. <i>Nature Reviews Cancer</i> , <b>2010</b> , 10, 213-21	31.3	192
12	Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. <i>Journal of Clinical Investigation</i> , <b>2010</b> , 120, 4332-41	15.9	577
11	Relapse after allogeneic hematopoietic cell therapy. <i>Biology of Blood and Marrow Transplantation</i> , <b>2010</b> , 16, S138-45	4.7	79
10	The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease. <i>Journal of Clinical Investigation</i> , <b>2010</b> , 120, 343-56	15.9	58
9	Gvhd, Hematopoietic Dysfunction, and Post-Transplant Immune Deficiency: Loss of Marrow Function Leads to Ineffective Extramedullary Hematopoiesis, However Lymphoid Reconstitution Is Restored by the Synergistic Effects of KGF, Sex Steroid Ablation, and Precursor T Cell Adoptive Therapy.. <i>Blood</i> , <b>2010</b> , 116, 1468-1468	2.2	
8	Genetic Engineering of Donor T Cells for BMT Immunotherapy: Expression of TRAIL and PLZF Selectively Enhances GVT and Abrogates Gvhd. <i>Blood</i> , <b>2010</b> , 116, 730-730	2.2	
7	Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses after murine allogeneic bone marrow transplantation. <i>Blood</i> , <b>2009</b> , 113, 1574-80	2.2	22
6	Disease-Free Survival After Cord Blood (CB) Transplantation Is Not Different to That After Related or Unrelated Donor Transplantation in Patients with Hematologic Malignancies.. <i>Blood</i> , <b>2009</b> , 114, 2296-2296	2.2	5
5	TRAIL/ DR5 Interactions Are Important for Thymic Damage After Allogeneic Bone Marrow Transplantation.. <i>Blood</i> , <b>2009</b> , 114, 234-234	2.2	
4	NOD2 Regulates Hematopoietic Cell Function During Graft-Versus-Host Disease.. <i>Blood</i> , <b>2009</b> , 114, 2453-2453		
3	The T Cell Cytolytic Molecules Fas Ligand and TRAIL, the Trafficking Molecules CCR9, $\alpha$ 4 $\beta$ 1 Integrin and PSGL-1, and the Immune Modulating Molecules OX40, CEACAM1, and CTLA4 Are Required for Thymic Graft-Versus-Host Disease. <i>Blood</i> , <b>2008</b> , 112, 65-65	2.2	10
2	Immunomodulatory Molecules of the Immune System <b>2007</b> , 67-121		
1	Distinct steps in the adsorption of pulmonary surfactant to an air-liquid interface. <i>Biophysical Journal</i> , <b>2000</b> , 78, 257-66	2.9	79